Table 2.
Demographics and baseline characteristics of patients by early responder status (SCALE Obesity and Prediabetes trial)
| Liraglutide 3.0 mg | Placebo | |||||
|---|---|---|---|---|---|---|
| All randomized (N = 2,487) | Early responders (N = 1,433) | Early nonresponders (N = 355) | All randomized (N = 1,244) | Early responders (N = 265) | Early nonresponders (N = 535) | |
| Female sex, n (%) | 1957 (78.7) | 1151 (80.3) | 251 (70.7) | 971 (78.1) | 205 (77.4) | 415 (77.6) |
| Mean age, years [SD] | 45.2 [12.1] | 46.4 [11.6] | 45.4 [11.8] | 45.0 [12.0] | 47.0 [11.7] | 45.6 [12.1] |
| Race, n (%) | ||||||
| White | 2107 (84.7) | 1238 (86.4) | 289 (81.4) | 1061 (85.3) | 240 (90.6) | 455 (85.0) |
| Black/African‐American | 242 (9.7) | 126 (8.8) | 41 (11.5) | 114 (9.2) | 15 (5.7) | 51 (9.5) |
| Other | 138 (5.5) | 69 (4.8) | 25 (7.0) | 69 (5.5) | 10 (3.8) | 29 (5.4) |
| Ethnicity, n (%) | ||||||
| Hispanic/Latino | 259 (10.4) | 126 (8.8) | 31 (8.7) | 134 (10.8) | 31 (11.7) | 46 (8.6) |
| Non‐Hispanic/Latino | 2228 (89.6) | 1307 (91.2) | 324 (91.3) | 1110 (89.2) | 234 (88.3) | 489 (91.4) |
| Mean weight, kg [SD] | 106.2 [21.2] | 105.3 [20.4] | 109.8 [23.7] | 106.2 [21.7] | 107.4 [23.6] | 106.7 [22.3] |
| Mean BMI, kg/m2 [SD] | 38.3 [6.4] | 38.1 [6.3] | 38.9 [6.8] | 38.3 [6.3] | 38.7 [7.1] | 38.3 [6.4] |
| Glycemic status, n (%) | ||||||
| Normoglycemic | 959 (38.6) | 528 (36.8) | 151 (42.5) | 487 (39.1) | 100 (37.7) | 196 (36.6) |
| With prediabetes | 1528 (61.4) | 905 (63.2) | 204 (57.5) | 757 (60.9) | 165 (62.3) | 339 (63.4) |
| Mean HbA1c, % points [SD] | 5.6 [0.4] | 5.6 [0.4] | 5.6 [0.4] | 5.6 [0.4] | 5.6 [0.4] | 5.6 [0.4] |
| Mean FPG, mg/dL [SD] | 95.9 [10.6] | 96.1 [10.4] | 97.2 [11.3] | 95.5 [9.8] | 95.7 [9.2] | 95.9 [9.9] |
Early responders, individuals who achieved ≥4% weight loss from baseline at 16 weeks; early nonresponders, individuals who achieved <4% weight loss from baseline at 16 weeks. Based on individuals with a fasting body weight measurement at baseline and week 16 and who completed 56 weeks of treatment. “All randomized” refers to all randomized patients in the overall trial.
BMI, body mass index; FPG, fasting plasma glucose; SD, standard deviation.